Overbought Stocks — Performance View · Pharmaceutical Preparations
30 stocks match the Overbought Stocks screen. Stocks with an RSI (14) above 70 — technically overbought, most-overbought first. Performance columns. Filtered to Pharmaceutical Preparations. Data as of close · Checked
| PCRX | Pacira Biosciences, Inc. | +0.10% | +47.11% | +42.40% | +53.85% | +64.22% | +40.85% | 0.1% | 1.8% | 2.70 | 61K | 36.42 | +0.10% | 165K |
| VRDN | Viridian Therapeutics, Inc.De | +19.77% | +59.47% | +29.08% | +65.89% | +25.51% | -6.67% | 7.5% | 6.3% | 5.52 | 148K | 29.05 | +15.62% | 819K |
| RDY | Dr Reddys Laboratories Ltd | +4.31% | +18.25% | +21.97% | +9.73% | +10.06% | +5.20% | 1.4% | 3.3% | 1.01 | 246K | 14.77 | +3.18% | 248K |
| INM | InMed Pharmaceuticals Inc. | +13.92% | +29.50% | +8.11% | +156.01% | -17.43% | +71.43% | 4.2% | 3.2% | 0.47 | 3K | 1.80 | +6.82% | 1K |
| LYEL | Lyell Immunopharma, Inc. | +41.34% | +80.30% | +9.10% | -26.23% | -5.67% | -49.72% | 9.0% | 8.2% | 6.90 | 8K | 15.47 | +42.98% | 53K |
| KRRO | Korro Bio, Inc. | +19.22% | +69.77% | +36.25% | +24.87% | -54.80% | +107.18% | 7.7% | 9.1% | 1.13 | 8K | 16.59 | +4.73% | 9K |
| XNCR | Xencor Inc | +17.16% | +43.68% | +74.98% | +169.46% | +151.83% | +128.80% | 5.9% | 6.3% | 1.38 | 82K | 35.03 | +14.33% | 113K |
| SLN | Silence Therapeutics Plc | +0.46% | +100.91% | +68.64% | +168.89% | +199.39% | +225.49% | 0.3% | 5.8% | 0.48 | 144K | 19.79 | +0.00% | 70K |
| LKFT | Lakefront Biotherapeutics Nv | +6.33% | +16.30% | +30.40% | — | — | +18.90% | 2.0% | 2.2% | 1.49 | 18K | 34.10 | +6.07% | 27K |
| ZTS | Zoetis | +14.60% | +24.99% | +15.45% | -19.82% | -38.27% | -29.14% | 2.8% | 2.3% | 1.70 | 205K | 89.16 | +7.40% | 347K |
| SNY | Sanofi | +12.31% | +19.86% | +10.58% | +8.46% | -5.21% | -2.17% | 2.1% | 1.7% | 2.11 | 211K | 47.44 | +4.65% | 446K |
| GMAB | Genmab A/S | -3.94% | +45.60% | +84.46% | +97.42% | +91.85% | +78.89% | 3.9% | 4.6% | 0.98 | 334K | 55.08 | -0.74% | 328K |
| LLY | Lilly (Eli) | +9.98% | +22.35% | +19.07% | +44.02% | +58.30% | +31.89% | 3.6% | 3.1% | 1.79 | 107K | 1418.07 | +0.62% | 192K |
| GRFS | Grifols Sa | +6.17% | +14.06% | +9.69% | +2.38% | -8.80% | -8.02% | 2.9% | 2.4% | 1.10 | 47K | 8.60 | +0.53% | 52K |
| DMAC | DiaMedica Therapeutics Inc. | +9.77% | +32.64% | +59.38% | +64.98% | +58.21% | +35.72% | 5.9% | 5.4% | 3.01 | 10K | 10.79 | +7.68% | 30K |
| RPRX | Royalty Pharma Plc | +4.21% | +19.72% | +18.05% | +33.31% | +81.10% | +74.84% | 2.1% | 2.3% | 0.97 | 208K | 67.56 | +1.82% | 202K |
| ABT | Abbott Laboratories | +12.56% | +16.95% | +7.07% | +33.44% | -6.68% | -7.76% | 2.4% | 2.5% | 2.06 | 453K | 115.57 | +5.61% | 933K |
| PHAR | Pharming Group N.V. | +10.95% | +29.20% | -0.39% | -21.51% | +2.46% | -25.32% | 1.6% | 1.5% | 0.06 | 524 | 12.92 | +0.31% | 29 |
| BBIO | Bridgebio Pharma, Inc. | +10.10% | +16.43% | -5.81% | +14.58% | +25.86% | +1.91% | 4.3% | 3.2% | 2.42 | 159K | 77.97 | +5.36% | 383K |
| AZN | Astrazeneca Plc | +11.43% | +19.18% | +17.37% | +2.20% | +15.64% | +2.78% | 1.9% | 1.8% | 2.15 | 164K | 189.00 | +2.77% | 352K |
| TRAX | First Tracks Biotherapeutics, Inc. | +7.37% | +56.62% | +8.30% | +143.19% | — | +164.40% | 5.9% | 8.2% | 1.31 | 56K | 49.13 | +5.93% | 74K |
| SEPN | Septerna, Inc. | +8.15% | +34.10% | +21.02% | +93.85% | +138.92% | +71.98% | 4.8% | 5.2% | 2.48 | 23K | 47.88 | +9.47% | 57K |
| BHC | Bausch Health Companies Inc. | +20.00% | +38.31% | +41.12% | +47.35% | +22.29% | +20.17% | 7.4% | 4.7% | 1.22 | 207K | 8.34 | +2.58% | 253K |
| UTHR | United Therapeutics Corp | +3.61% | +12.11% | +14.03% | +1.86% | +38.55% | +24.74% | 2.5% | 2.8% | 1.68 | 40K | 607.43 | +0.95% | 68K |
| TAK | Takeda Pharmaceutical Co Ltd | +4.54% | +16.32% | +23.66% | +25.99% | +56.97% | +35.21% | 2.0% | 1.5% | 1.33 | 154K | 21.07 | +1.47% | 205K |
| ZYME | Zymeworks Inc. | +7.02% | +20.62% | +33.51% | +12.02% | +63.83% | +17.55% | 3.2% | 4.6% | 0.92 | 44K | 30.94 | +2.69% | 40K |
| ELAN | Elanco Animal Health Inc | +11.67% | +12.54% | +4.61% | -3.21% | +10.67% | +11.84% | 2.8% | 3.7% | 1.88 | 489K | 25.31 | +2.97% | 920K |
| NVS | Novartis Ag | +5.74% | +17.22% | +7.05% | +11.28% | +33.18% | +19.65% | 1.6% | 1.6% | 1.00 | 115K | 165.02 | +3.64% | 116K |
| ORKA | Oruka Therapeutics, Inc. | +5.71% | +26.57% | +3.19% | +45.51% | +287.48% | +234.70% | 4.4% | 5.7% | 0.72 | 56K | 101.48 | +1.85% | 40K |
| PVLA | Palvella Therapeutics, Inc. | +10.15% | +25.60% | +5.18% | +25.17% | +112.40% | +55.47% | 5.9% | 6.2% | 2.57 | 13K | 162.66 | +6.31% | 34K |
Source: SEC EDGAR/XBRL (fundamentals, shares) · Databento EQUS.MINI (EOD prices) · multiples, ratios & technicals computed by tradmap. Financials: Trailing twelve months where four consecutive quarters are reported, otherwise the latest fiscal year; revenue is the fiscal-year figure where quarterly revenue covers under half of it (typical for banks, insurers and REITs), and margins are taken on it. A company reporting in another currency is shown in ≈ USD: its figures convert at the Federal Reserve H.10 rate of its price date (FRED), and without a rate its multiples are blank. This product uses the FRED® API but is not endorsed or certified by the Federal Reserve Bank of St. Louis. Informational only — not financial advice.